Drug intelligence / Profile preview

pyranopyridine efflux pump inhibitors

Development stage: Preclinical
Lead developer: Microbiotix
Modality: Small Molecules

Overview

Pyranopyridine efflux pump inhibitors are a class of small molecule inhibitors developed by Microbiotix to target the AcrAB-TolC Resistance-Nodulation-Division (RND) efflux pump system in Gram-negative bacteria. By blocking these pumps, which are a primary mechanism for antibiotic resistance in Enterobacteriaceae, these compounds are designed to potentiate the activity of existing FDA-approved antibiotics, restore their efficacy against multi-drug resistant (MDR) strains, and reduce the emergence of further resistance. The program is currently in the lead optimization stage, focusing on treating infections caused by pathogenic and carbapenem-resistant Enterobacteriaceae (CRE).

Other names: pyranopyridine EPIsefflux pump inhibitors

Targets

AcrB

Beyond the preview

Go deeper on pyranopyridine efflux pump inhibitors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pyranopyridine efflux pump inhibitors.

Explore the full profile